Mabwell has reported early clinical evidence suggesting that blocking the IL-33/ST2 inflammatory pathway could reduce exacerbations in patients with moderate-to-severe chronic obstructive pulmonary disease. The randomized, double-blind Phase 1b/2a study enrolled 80 former smokers and tested 100 mg, 300 mg, 600 mg and 900 mg doses of investigational anti-ST2 monoclonal antibody 9MW1911 administered intravenously every four weeks against placebo. In the two higher-dose groups, annualized moderate-to-severe COPD exacerbation rates were numerically reduced by 24% at 600 mg and 81% at 900 mg compared with placebo.
The company also reported 47% and 100% numerical reductions in severe exacerbations at 600 mg and 900 mg, respectively. Those headline figures are attention-grabbing because COPD exacerbations can accelerate lung-function decline, lead to hospitalization and increase mortality risk, but this was primarily a safety, tolerability and pharmacokinetic study rather than a large trial powered to establish definitive efficacy. The right interpretation is therefore that 9MW1911 generated a dose-related preliminary efficacy signal strong enough to justify larger testing, not that an 81% or 100% reduction has already been proven for routine COPD treatment.
Why is the IL-33 and ST2 pathway attracting interest as a COPD treatment target?
COPD is not one uniform inflammatory disease. Cigarette-smoke exposure and other insults can produce persistent airway inflammation involving epithelial cells, innate immune responses, eosinophils, neutrophils and multiple cytokine pathways, which helps explain why treatments that work extremely well in one biological subgroup may be less effective in another. IL-33 is an epithelial-derived cytokine released during tissue stress and injury, while ST2 functions as a receptor through which IL-33 can activate downstream inflammatory responses.
9MW1911 is designed to bind ST2 and prevent IL-33-driven signaling. Mabwell’s hypothesis is that interrupting this pathway could dampen chronic inflammatory activity and reduce the likelihood that infections, pollutants or other triggers push a patient into an acute COPD exacerbation. The mechanism is particularly interesting because the Phase 1b/2a population was not restricted to patients with very high blood eosinophils, potentially pointing toward a different biological segment from some of the better-established type 2 inflammatory strategies.
What exactly did the 80-patient Phase 1b/2a 9MW1911 study test?
The 9MW1911-C03 trial was randomized, double-blind, placebo-controlled and designed around multiple ascending doses. Former smokers with moderate-to-severe COPD received 100 mg, 300 mg, 600 mg or 900 mg of 9MW1911 by intravenous infusion every four weeks, while another group received placebo. The main goals were safety, tolerability and pharmacokinetics, with COPD exacerbations included as an exploratory or preliminary efficacy measure rather than the central powered endpoint.
Mabwell reported broadly balanced demographic characteristics across treatment groups and noted that most participants had blood eosinophil counts at or below 300 cells per microliter. Pharmacokinetic exposure increased approximately proportionally across the 100 mg-to-900 mg dose range, while trough concentrations reached steady state at around week 12. These findings provide the dose-exposure information needed to plan later trials while also helping developers identify whether higher doses produce enough additional biological activity to justify greater drug exposure.
Why is the 81% exacerbation reduction encouraging but not yet definitive evidence?
An 81% reduction in moderate-to-severe exacerbations at the highest dose is much larger than the effect commonly expected from established COPD maintenance therapies, which immediately raises the evidentiary bar. With only 80 patients spread across five groups, the number of exacerbation events in any individual dose cohort may be small, allowing a few additional or avoided events to shift annualized percentages substantially. Mabwell itself describes the efficacy findings as preliminary signals and numerical trends rather than presenting the trial as confirmatory.
The severe-exacerbation result deserves even greater caution. A reported 100% numerical reduction at 900 mg means no qualifying severe events occurred in that group during the relevant period, not that the drug can be expected to eliminate severe COPD exacerbations entirely in a large population. Phase 2b and Phase 3 studies with hundreds or thousands of patients and longer observation will be necessary to estimate the true effect much more precisely.
Could 9MW1911 address patients who are not strongly eosinophilic?
That possibility is one of the more strategically interesting aspects of the program. Many participants in the Phase 1b/2a study had blood eosinophil counts no higher than 300 cells per microliter, meaning the study was not simply enriched for an extremely eosinophilic COPD phenotype. Mabwell is therefore exploring whether IL-33/ST2 blockade can influence exacerbation biology across a population that may not overlap completely with patients selected for other biologic approaches.
It would be premature, however, to conclude that the treatment is equally effective regardless of eosinophil level. Subgroup analyses from larger trials will need to determine whether baseline eosinophils, smoking history, exacerbation frequency, chronic bronchitis, emphysema or other features predict response. If a biomarker ultimately identifies patients most likely to benefit, that could make 9MW1911 easier to position clinically than an indiscriminate biologic strategy applied across all COPD.
What did Mabwell report about safety as the dose increased to 900 mg?
Mabwell described the overall safety and tolerability profile as favorable across the evaluated dose range. The study was designed specifically to detect dose-related safety issues and establish how the antibody behaved pharmacokinetically before moving into larger efficacy-focused testing. No major new safety concern was highlighted in the September results announcement.
Later-stage studies will nevertheless matter enormously because COPD patients are often older and frequently have cardiovascular disease, metabolic disorders and recurrent respiratory infections. Any long-term immune-modulating therapy has to be evaluated not only for infusion reactions or laboratory abnormalities but also for whether changing inflammatory signaling affects infection susceptibility or other clinically important outcomes. An 80-patient early trial cannot reliably detect uncommon adverse events.
Where is Mabwell taking 9MW1911 after the Phase 1b/2a signal?
Mabwell has already completed enrollment in a larger Phase 2b study in COPD, indicating that development has moved beyond the exploratory stage. The company expects to initiate a Phase 3 program around the end of 2026, while the U.S. FDA has separately cleared an IND allowing a Phase 2a study in moderate-to-severe COPD in the United States.
This creates an important sequencing issue. The Phase 2b study should provide a more reliable estimate of dose response and exacerbation reduction before the company commits fully to pivotal development, while U.S. clinical work can broaden the geographic evidence base. If the striking high-dose signal weakens materially in a larger population, the September numbers will look like an early-trial fluctuation; if a substantial reduction persists, 9MW1911 could emerge as a significant competitor in biologic COPD treatment.
Why is preventing COPD exacerbations clinically more important than simply improving daily symptoms?
An exacerbation is not merely a temporary period of worse coughing or breathlessness. Moderate and severe episodes can require corticosteroids, antibiotics, emergency care or hospitalization, and patients often do not return fully to their previous baseline afterward. Recurrent exacerbations are associated with deteriorating lung function, poorer quality of life and increased healthcare utilization.
That means a medicine capable of materially reducing exacerbation frequency can have an impact extending beyond symptom scores obtained during routine clinic visits. The challenge is that COPD trials require enough follow-up and enough events to demonstrate such benefits robustly. Mabwell’s early results provide a reason to invest in that larger experiment, but the commercial and clinical value of 9MW1911 will depend on reproducing the signal under conditions designed specifically to test exacerbation prevention.
What should respiratory specialists watch when the larger 9MW1911 dataset arrives?
Dose response will be one of the first questions. The 900 mg cohort produced a much stronger numerical exacerbation result than 600 mg, which could represent greater pathway inhibition, random variation or differences in baseline patient characteristics. Phase 2b data should help determine whether efficacy rises consistently with exposure and whether a practical dose can maintain benefit without creating additional safety burden.
The second issue is biomarker selection. If 9MW1911 works well in patients with lower eosinophil levels, it could address an important population for whom biologic treatment options remain more limited. For now, an 81% reduction in moderate-to-severe exacerbations is best viewed as a provocative early signal from an 80-patient study, while the Phase 2b and expected Phase 3 programs will decide whether anti-ST2 therapy can genuinely become part of mainstream COPD management.
